Profusa, Inc. Common Stock
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jack E. Stover
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 626 Bancroft Way, Suite A Berkeley CA United States of America 94710
- IPO Date
- Jul 14, 2025
- CIK
- 0001859807
- Website
- profusa.com
- Similar Companies
- Business
- Profusa, Inc. is a digital health innovator engineering advanced tissue-integrated biosensors to consistently track an individual's internal body chemistry, delivering intelligent, data-driven health insights for managing long-term conditions. The company's Lumee™ Oxygen Platform, which has received CE Mark approval for European use, employs micro-sensors and optical readers to provide real-time tissue oxygen levels, addressing needs in peripheral artery disease, chronic wounds, and reconstructive surgery. Profusa is also progressing toward a continuous glucose monitoring system for diabetes management, aiming to harness AI for personalized medical data directly from within the body to inform treatment and improve outcomes.
Company News
Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement
Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company
Profusa Announces 1-for-4 Reverse Stock Split
Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs
Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company
Profusa Announces 1-for-25 Reverse Stock Split
Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts
Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting
Profusa Announces Listing Transfer to The Nasdaq Capital Market
Profusa Receives Favorable Nasdaq Listing Determination
Profusa Receives Favorable Nasdaq Listing Determination
Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value
What's Going On With Profusa Stock Tuesday?
Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform
Why Applied Optoelectronics Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Analyzing Profusa (NASDAQ:PFSA) & Medline (NASDAQ:MDLN)
Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering
CapsoVision (NASDAQ:CV) and Profusa (NASDAQ:PFSA) Head-To-Head Review